Latest and live tenders published in all country. Click on any tender to view further details.

supply of production of high value, human consumption pulses in australia is dominated by lentil and chickpea, and is concentrated on the more fertile soils in the medium rainfall areas of the southern and northern regions. due to the farming system benefits of imposing a double break and the high prices in recent years, there is much interest in expanding lentil and chickpea production onto soils with a number of constraints acidity, nutrient toxicities and deficiencies, poor structure and into other rainfall zones. it is critical that new pulses be developed and managed such that the crop life-cycle fits within the constraints of availability of soil water, frost and heat stresses and flowering and pod-set occur in the optimum window for different agroecological zones. as time to flowering and pod-set are so critical in these crops, understanding and improving them in existing production regions and where they have not been optimised yet is one of the most critical elements that can contribute to their adoption and deliver potential step changes in yield and profit. the national pulse phenology investment proposed will utilise common genetic resources across existing and potential pulse expansion regions of australia to expedite delivery of data, tools and knowledge which can inform crop breeding. it will leverage international r&d activities, and new synergies provided by recent developments in understanding of genome synteny and conserved pathways in this group of crops to deliver on investment outputs. what is new there is a gap in understanding of the genetic control underlying phenology in pulse crops chickpea and lentil which underpins ‘fitting’ crop growth into the best timeframe for target production environments. the genes/ quantitative trait loci qtl identified will present the opportunity to: idetermine the genetic basis of contrasting adaptation characteristics of chickpea and lentil, iimatch critical phenological stages to the constraints and opportunities of the target environment, iiiidentify genetic and environmental factors controlling the rate of phasic development and reproductive survival across a range of target environments to inform breeding decisions and growers choice of varieties. knowledge of the effect of different phenology gene/allele combinations of pulse crops across diverse environments will facilitate the development of new varieties with higher yield potential and better yield stability than currently available in existing production zones and potential expansion areas. this will not only maintain the sustainability of the pulses in their traditional areas but facilitate growth and expansion into new target production environments. this is of particular relevance to the western region where the current production area of both crops is low <5, 000 ha but the potential is high, particularly for chickpeas as an alternative to lupin. access to improved varieties and knowledge will help growers match the life-cycle of pulse crops to australian growing conditions and close the gap between achieved versus potential yield, increasing farm productivity and profitability. investment description this investment aims at comprehensive characterisation of major genes and loci controlling phenology/flowering time, a key adaptation trait, in cultivated chickpea and lentil and their wild relatives. the investment will generate a comprehensive, high-quality dataset of chickpea and lentil phenology flowering, beginning and end of pod-set, maturity from field trials with locations in the three growing regions, controlled environment facilities, and large samples of diverse genetic material. this data set will be a critical input to the: agenetic analyses, the focus of this investment bgenerating critical datasets for potential modelling r&d to support risk analysis cfarming systems agronomy research. expected outcome profitable pulse crops as part of the farming system that contributes to enduring profitability for australian grain growers. by 2023, australian chickpea and lentil breeders have access to genetic and phenotyping tools to improve the matching of variety and environment for established and emerging production environments. expected outputs by 2022, 1.knowledge of genetic and environmental control of chickpea and lentil phenology including identification of qtls/genes controlling flowering, beginning and end of pod-set and maturity delivered to australian breeders. 2.a genetic database that accounts for the variation in phenology of existing australian chickpea and lentil varieties, and key pre-breeding and breeding lines. this database will be available for breeders to select parents for breeding crosses and for informing predictive models. 3.comprehensive, high-quality datasets of grain yield, linked to phenology, for a targeted set of latitudes and thermal environments. these data will be used in two ways. first, to develop tools that will guide breeders in the choice of parents to be used in crossing for developing varieties with potential to match phenological development of high yielding chickpea and lentil varieties to their target production environment. second, generate data that will contribute in further r&d efforts towards developing crop simulation models which will assist growers in risk analysis in decisions around chickpea and lentil production. 4.knowledge of the optimal phase development patterns of high yielding chickpea and lentil germplasm, within a defined set of relevant australian target production environment types. https://grdc.com.au/research/applying-and-reporting/current-procurement/open-tenders/improving-the-adaptation-and-profitability-of-high-value-pulses-chickpea-and-lentil-across-australian-agroecological-zones

recent incursion of the barley disease ramularia has not been fully delimited around the areas of confirmed occurrence. as this disease can spread through infected seed, growers in these regions will need information on the relative risk of saving seed for planting the following year. other regions that currently have had no positive recordings will need to be surveyed to ensure that these areas are currently free from ramularia. ramularia in the northern hemisphere and new zealand has recently increased in pathogen aggressiveness, decreased in fungicide sensitivity and caused epidemics in germany. determining the occurrence of ramularia across the australian grain belt will inform the level of disease management options required including seed hygiene, fungicide and pre-breeding investments. investment description this investment will combine three surveillance approaches over two seasons to determine the incidence and distribution of ramularia across the australian grain belt. 1. delimiting ramularia incidence around existing confirmed occurrences; 2. where found, collection and storage of ramularia samples for further characterisation; 3. determining the areas that are free of the disease with emphasis on areas known to be of highest disease risk across the western, southern and northern grdc regions. there is a preference for a coordinated national approach. expected outcome by 2022, australian grain growers will be implementing effective disease management strategies that minimise the impact of priority diseases on production leading to at least 10% increase in profitability expected outputs by december 2019 and annually thereafter, australian grain growers will know the incidence and distribution of ramularia across the australian grain belt. details: a ramularia occurrence survey to be conducted across the australian grain belt with an emphasis on the high and medium rainfall regions. a delimitation survey will be conducted in western australia.

department is seeking the supply and delivery of: unprinted plastic dual frequency proximity cards proximity cards; and blank plastic pvc cards pvc cards.

provision of logistics and letter services under a panel arrangement. the services are separated into 3 categories: general warehousing and distribution of publications and forms; personalisation and mailing of letters; bulk distribution of digital communication.

provision of printing and production services under a panel arrangement. the services are separated into 16 different categories: print on demand; digital black and colour printing and finishing – small format up to a3; digital black and colour printing and finishing – large format above a3; sheet offset black and colour printing and finishing <1, 000 units; sheet offset black and colour printing and finishing >1, 000 units; heatset web / coldset web black and colour printing and finishing; form printing and finishing; envelope printing and finishing; file cover printing and finishing; security documents printing and finishing; corporate merchandise; specialised printing services; custom finishing services; duplication services; braille and specialist services; and customised plastic products.

falling number fn is a global industry standard used to quantify detrimental pre-harvest sprouting phs in wheat, as early release from seed dormancy leads to significant effects on end product quality. however, a low falling number can also be caused by the trait of late maturity alpha-amylase lma, with some wheats having a genetic predisposition to accumulate low levels of starch digesting enzymes during grain filling in the absence of sprouting. lma susceptibility is currently a classification criterion for milling wheat in australia. due to the cost involved in the current lma susceptibility screen, it is currently employed at a late phase in the breeding pathway of australian wheat breeding programs, which significantly restricts genetic gains for yield and other traits in australian wheat varieties. investment description this investment is one of three interrelated investments aimed at managing and eliminating the effect of late maturity alpha-amylase lma in wheat through improved phenotyping and modelling: proc-9176016 lma project a – improved phenotyping for late maturity alpha-amylase lma susceptibility in wheat; proc-9176017 lma project b – a novel high-throughput, low-cost test to determine cause of starch damage in wheat grain; and lma project c – an improved model of late maturity alpha-amylase lma field risk in australian wheat. this procurement focusses on the development of an innovative lma susceptibility screening methodology that has increased throughput, scalability, repeatability and significantly reduced costs in comparison to the current benchmark assay. it is expected that the successful applicant will propose a multi-disciplinary approach with potential inputs from fields such as phenomics, molecular biology, biometrics, plant physiology, plant breeding and genetics. innovative solutions may also borrow from other disciplines such as robotics, medical sciences, mathematics and engineering. the successful applicant will be expected to actively engage with industry stakeholders australian wheat breeding companies and wheat quality australia as well as the successful applicant of ‘lma project c – an improved model of late maturity alpha-amylase lma field risk in australian wheat’. expected outcome by 2030, late maturity alpha-amylase lma risk is managed within the australian wheat industry as to maximise genetic gains and minimise downgrades to improve enduring profitability for australian growers. intermediate outcome by 2023, australian industry will have access to accurate, high-throughput screening tools for lma expression that are employable early in breeding programs, research programs and applicable to a more cost effective, higher throughput lma classification screen; growers will have the ability to determine starch damage of grain on-farm; and the industry as a whole will have access to accurate field risk profiles of lma to inform decision making. this will be achieved through the three interrelated investments. expected output output 1 by 2023, an improved lma susceptibility screening methodology with increased throughput, scalability, repeatability and decrease cost in comparison to the current benchmark assay. contracting the investment will be contracted on a grdc standard research agreement two party. full details here: https://grdc.com.au/research/applying-and-reporting/current-procurement/open-tenders/lma-project-a-improved-phenotyping-for-late-maturity-alpha-amylase-lma-susceptibility-in-wheat/

falling number fn is a global industry standard used to quantify detrimental pre-harvest sprouting phs in wheat, as early release from seed dormancy leads to significant effects on end product quality. however, a low falling number can also be caused by the trait of late maturity alpha-amylase lma, with some wheats having a genetic predisposition to accumulate low levels of starch digesting enzymes during grain filling in the absence of sprouting. lma susceptibility is currently a classification criterion for milling wheat in australia. investment description this investment is one of three interrelated investments aimed at managing and eliminating the effect of late maturity alpha-amylase lma in wheat through improved phenotyping and modelling: proc- 9176016 lma project a – improved phenotyping for late maturity alpha-amylase lma susceptibility in wheat proc- 9176017 lma project b – a novel high-throughput, low-cost test to determine cause of starch damage in wheat grain; and lma project c – an improved model of late maturity alpha-amylase lma field risk in australian wheat. this tender is for the development of a rapid, mobile, low-cost test for starch degradation in wheat grains which can also determine the cause of damage as lma or phs. such a test will be valuable to breeders and pre-breeders seeking to determine the cause of starch damage in breeding material and research populations in the field, increasing the speed at which lma susceptibility can be controlled by genetics. the technology could also be used by growers to aid post-harvest decision making and by grain receivers to rapidly and reliably determine starch damage. it is expected that the successful applicant will propose an innovative approach that may include imaging science, biochemistry and/or molecular biology. the proposed approach may also borrow from other disciplines such as medical sciences, food sciences, physics and engineering. a proof of concept of the proposed approach will be highly regarded in assessment. the tender is open to private, public and private-public partnerships. expected outcome by 2030, late maturity alpha-amylase lma risk is managed within the australian wheat industry as to maximise genetic gains and minimise downgrades to improve enduring profitability for australian growers. intermediate outcome by 2023, australian industry will have access to accurate, high-throughput screening tools for lma expression that are employable early in breeding programs, research programs and applicable to a more cost effective, higher throughput lma classification screen; growers will have the ability to determine starch damage of grain on-farm; and the industry as a whole will have access to accurate field risk profiles of lma to inform decision making. this will be achieved through the three interrelated investments. expected output output 1 by 2023, test developed to quantify starch damage and determine the cause as lma and/or phs. contracting the investment will be contracted on a grdc standard research agreement two party. for full details: https://grdc.com.au/research/applying-and-reporting/current-procurement/open-tenders/lma-project-b-a-novel-high-throughput, -low-cost-test-to-determine-cause-of-starch-damage-in-wheat-grain/

supply of suitably qualified organisations to participate in a potential multi-stage procurement process for the provision of innovative solutions to enhance the department’s unified communications.

supply of brain cancer is the sixth leading cause of cancer burden and there are more than 100 types of brain cancer and other central nervous system cancers. these cancers carry high rates of morbidity and mortality. the five-year relative survival rate for brain cancer is low, at around 22 per cent. the young are disproportionately affected by brain cancer and brain cancer kills more children in australia than any other disease. despite improvements in patient care and support, survival rates for brain cancer have remained relatively unchanged for the past 30 years. the australian brain cancer mission the mission was announced on 29 october 2017 and aims to double survival rates and improve the quality of life for patients with brain cancer over ten years to 2027, with the longer term aim of defeating brain cancer. as at july 2019, $124.7m had been committed to the mission through co-investments from philanthropy, non-government organisations and governments, including $58.35m from the australian government through the medical research future fund mrff. cancer australia is responsible for administering the mission, supported by a strategic advisory group msag. a national brain cancer research roundtable was convened in 2017 bringing together people affected by brain cancer and their families, leading australian and international researchers, clinicians, advocacy and philanthropic groups. this roundtable provided the framework for delivery on the aim of the mission and developed a research roadmap that articulates the mission’s investment strategies. conducting an ‘analysis of australian brain cancer platforms and technologies’ is one of the early and immediate priorities for implementation outlined in the research roadmap. the purpose of the analysis is to inform future national infrastructure requirements and their use; identify networking strategies to enhance utilisation for platform and technology systems, and reduce duplication in effort; facilitate better coordinated use of platforms and technologies which will play a significant role in supporting brain cancer research, clinical trials, early detection, diagnosis, treatment and clinical care for children, adolescents and young adults aya, and adults with brain cancer for the next 3 – 5 years, and to 2027. scope: the scope of the analysis will cover platforms and technologies applicable to children, aya and adults with brain cancer across the brain cancer continuum of care, which for the analysis, will include brain cancer research, clinical trials, early detection, diagnosis, treatment, and clinical care. outcomes and reporting requirements: the analysis will inform future national infrastructure requirements, including how resources can be coordinated to play a significant role in supporting the brain cancer continuum of care for children, aya, and adults. the analysis will also identify existing platforms and technologies, as well as potential new platforms and technologies. in undertaking this work, the contractor will be required to provide cancer australia with monthly updates by teleconference, two progress reports, a draft final report and a final report. the two progress reports, the draft final report and the final report will also be considered by msag. the final report will include: 1.a review outlining brain cancer platforms and technologies that are currently available nationally and internationally, and how they are being used in australia; 2.a review of platforms and technologies currently used in cancer research and clinical trials, and where relevant, how these platforms and technologies can be incorporated across the brain cancer continuum of care to inform potential future investments under the mission over the next 3 - 5 years; and to 2027; 3.a review and the analysis of consultations with relevant experts identifying current platforms and technologies, and potential new platforms and technologies, that could inform the next investments under the mission to support the brain cancer continuum of care in australia, specifically: a. what is needed over the next 3 - 5 years; and b. what is on the horizon to 2027; and 4.an analysis of consultations with relevant experts identifying the workforce requirements, capacity, capability and training needs for the next 3 - 5 years and up to 2027, to support future investments in brain cancer platforms and technologies. 5.a gap analysis to inform future requirements across the brain cancer continuum of care in the next 3 – 5 years, and to 2027. the gap analysis will include: a.approaches to enhance utilisation of platform and technology system networks; b.proposals for how current and potential new platforms and technologies utilising large data sets and bioinformatics, can aid in achieving the aim of the mission; c.potential strategies for reduction of any identified duplications in resources in relation to brain cancer platforms and technologies across the continuum of care; and d.potential strategies to facilitate more efficient coordinated use of brain cancer platforms and technologies. 6.a cost-benefit analysis for upscaling current platforms and technologies, and introducing potential new platforms and technologies, to fill identified validated gaps from the above gap analysis. the cost-benefit analysis will include the costs and benefits to patients and the healthcare system in the next 3 – 5 years, and up to 2027, to inform potential future investments under the mission. 7.a plan for upscaling existing platforms and technologies, and the introduction of potential new platforms and technologies, including considerations for the identified critical parameters and elements, required for the upscaling and introduction of these platforms and technologies, to achieve expansion of the brain cancer continuum of care in the next 3 – 5 years and up to 2027. partnerships: cancer australia encourages the partnering of different organisations, departments, and groups to bring together the necessary skills and experiences to provide a tender to undertake the analysis. the organisational structure and management of staff involved in the partnership should be outlined in the tender. timeframe: the project is planned to commence in november 2019 and to be completed within six months of the start date. funding of up to $450, 000 gst inclusive has been provided from the department of health to cancer australia for the purpose of procuring a suitably qualified organisation to undertake this work.

provision of internal audit services, further details of the requirement are set out in schedule 1 statement of requirement.